SCHEMBL1483291

SCHEMBL1483291

C[C@]12[C@H](CC[C@@H]3[C@@H]1C[C@@H](O)[C@]1(C)[C@@H](c4ccc(=O)oc4)CC[C@]31O)C[C@@H](O)C[C@H]2O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP1A1 P05023 6/20 0.58
ATP1B1 P05026 6/20 0.58
ATP1A3 P13637 6/20 0.58
ATP1B2 P14415 6/20 0.58
ATP1A2 P50993 6/20 0.58
ATP1B3 P54709 6/20 0.58
FXYD2 P54710 6/20 0.58
ATP1A4 Q13733 6/20 0.58
CYP3A4 P08684 3/20 0.58
CYP3A5 P20815 2/20 0.58
AR P10275 1/20 0.58
ZFP91 Q96JP5 1/20 0.58
STAT3 P40763 2/20 0.49
CYP3A7 P24462 1/20 0.49
TP53 P04637 6/20 0.47
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
LMNA P02545 5/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
PAX8 Q06710 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5082699 0.86 ATP1A1 (0.75) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL1483302 0.86 ATP1A1 (0.75) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL1483855 0.78 ATP1A1 (0.62) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufarenogin SCHEMBL21578316 0.76 ATP1A1 (0.67) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufarenogin SCHEMBL21578186 0.76 ATP1A1 (0.67) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL5080351 0.74 ATP1A1 (0.73) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL5079321 0.74 ATP1A1 (0.62) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL23382204 0.74 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL21129737 0.74 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Bufalin SCHEMBL21083171 0.74 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110076278-A1 Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders BIONAUT PHARMACEUTICALS INC 2011-03-31 US claimed
US-20110076278-A1 Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders BIONAUT PHARMACEUTICALS INC 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110076278-A1 Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders HIF1A, HIF1AN, HYOU1 ATP1A1 307/4885ATP1B1 102/4885ATP1A3 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.